Today: 9 June 2026
Browse Category

SGX:H78.SI 21 December 2025 - 29 January 2026

Hongkong Land stock jumps on fresh buyback filing — $7.77 is the level to watch

Hongkong Land stock jumps on fresh buyback filing — $7.77 is the level to watch

Hongkong Land shares rose 3.2% to $7.73 in Singapore after the developer disclosed a buyback of 190,000 shares for cancellation on Jan. 9. The stock has gained about 11% since the start of the year. Investors await further buyback news and early March results for signals on property values. The company’s issued share capital now stands at 2,157,649,126 shares.
11 January 2026
··
Hongkong Land (H78) Stock: Singapore Private Fund Catalyst, Buybacks, and What Forecasts Say for 2026

Hongkong Land (H78) Stock: Singapore Private Fund Catalyst, Buybacks, and What Forecasts Say for 2026

Hongkong Land closed at US$6.92 on Dec. 19, 2025, remaining below its 52-week high. The company agreed to sell its 33.33% stake in MBFC Tower 3 for S$1.5 billion, pushing capital recycling proceeds since 2024 to US$2.8 billion. Its planned Singapore Central Private Real Estate Fund is set to launch with over S$8 billion in assets, with further details expected in Q1 2026.
21 December 2025

Stock Market Today

  • GSK to Acquire Nuvalent for $10.6 Billion to Boost Oncology Pipeline
    June 9, 2026, 9:41 AM EDT. GSK announced a $10.6 billion cash acquisition of U.S.-based Nuvalent, offering $124 per share, a 40% premium. The purchase aims to strengthen GSK's oncology portfolio ahead of patent expiries on key HIV treatments. Nuvalent awaits FDA decisions on two lung cancer drugs, zidesamtinib and neladalkib, with potential 2027 market entry. The deal also includes earlier-stage cancer treatments, including NVL-330. Nuvalent shares rose nearly 39% premarket, while GSK shares slipped 1.4%. GSK plans to finance the deal through debt and cash, expecting sales and profit boosts from 2027 and 2029, respectively, without impacting its credit rating. The acquisition intensifies GSK's lung cancer market presence, competing with firms like AstraZeneca, Roche, and Pfizer.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Go toTop